Moreover, the confirmatory role of ASXL1 and NRAS mutations in influencing CMML prognosis, consistent with broader literature, emphasizes the potential of targeted therapies and highlights the need for enhanced predictive tools. Here, ASXL1 is linked to chronic myelomonocytic leukemia.